Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

NCT02606461 is registered in ClinicalTrials.gov with Karyopharm Therapeutics Inc as lead sponsor.

NCT NCT02606461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02606461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Lead sponsor
Karyopharm Therapeutics Inc
Phase
Phase 2/3
Overall status
Completed
Start date
January 4, 2016
Completion date
October 26, 2021
Enrollment
342 (actual)
Sites
71

Conditions

As the registry lists them; a condition with its own page is linked.

dedifferentiated liposarcoma